Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 2873 entries
View as:

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

Phase: N/A Priority: Normal
NCT ID: NCT00941928 Org: User:
Start: 07/31/09 End: 05/31/12 Due: 05/31/13

Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00495040 Org: User:
Start: 05/04/06 End: 06/14/17 Due: 06/14/18

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01087554 Org: User:
Start: 03/31/10 End: 08/18/26 Due: 08/18/27

An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction

Phase: N/A Priority: Normal
NCT ID: NCT03990610 Org: User:
Start: 05/24/19 End: 04/30/26 Due: 04/30/27

Cancer Patients' Medication Knowledge in the Emergency Center

Phase: N/A Priority: Normal
NCT ID: NCT00385476 Org: User:
Start: 08/31/05 End: 02/28/09 Due: 02/28/10

Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT00656617 Org: User:
Start: 04/30/08 End: 02/28/14 Due: 02/28/15

Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia

Phase: N/A Priority: Normal
NCT ID: NCT04984551 Org: User:
Start: 08/24/20 End: 12/31/26 Due: 12/31/27

Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00866749 Org: User:
Start: 09/12/06 End: 07/26/18 Due: 07/26/19

A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00038584 Org: User:
Start: 06/30/99 End: 11/30/04 Due: 11/30/05

Long-Term Follow-Up of Recipient of Gene Transfer Research

Phase: N/A Priority: Normal
NCT ID: NCT01492036 Org: User:
Start: 12/09/11 End: 12/31/27 Due: 12/31/28

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

Phase: N/A Priority: Normal
NCT ID: NCT03225664 Org: User:
Start: 02/03/18 End: 12/31/25 Due: 12/31/26

Motivational Interviewing for Physical Activity

Phase: N/A Priority: Normal
NCT ID: NCT01008787 Org: User:
Start: 07/28/09 End: 07/31/25 Due: 07/31/26

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients with Locally Advanced or Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03587662 Org: User:
Start: 08/17/18 End: 01/31/27 Due: 01/31/28

Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases

Phase: N/A Priority: Normal
NCT ID: NCT03599752 Org: User:
Start: 07/02/18 End: 01/31/30 Due: 01/31/31

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00085384 Org: User:
Start: 07/31/02 End: 04/30/07 Due: 04/30/08

Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03219047 Org: User:
Start: 12/20/18 End: 07/03/23 Due: 07/03/24

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT00880815 Org: User:
Start: 02/17/09 End: 05/28/19 Due: 05/28/20

Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study

Phase: N/A Priority: Normal
NCT ID: NCT04652505 Org: User:
Start: 07/13/20 End: 01/12/22 Due: 01/12/23

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03202316 Org: User:
Start: 08/11/17 End: 12/31/25 Due: 12/31/26

Azacytidine and Valproic Acid in Patients With Advanced Cancers

Phase: N/A Priority: Normal
NCT ID: NCT00496444 Org: User:
Start: 05/31/05 End: 10/31/09 Due: 10/31/10

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Phase: N/A Priority: Normal
NCT ID: NCT01946165 Org: User:
Start: 10/31/13 End: 07/28/17 Due: 07/28/18

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03989466 Org: User:
Start: 01/15/20 End: 09/24/24 Due: 09/24/25

Perioperative Care in the Cancer Patient -1, ARCA-1 Study

Phase: N/A Priority: Normal
NCT ID: NCT04491409 Org: User:
Start: 08/03/20 End: 11/17/23 Due: 11/17/24

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03019640 Org: User:
Start: 10/10/17 End: 08/16/21 Due: 08/16/22

Pneumoperitoneum Management With Low vs. Higher Pressure

Phase: N/A Priority: Normal
NCT ID: NCT03128281 Org: User:
Start: 07/31/18 End: 07/31/22 Due: 07/31/23